Deadline Many Canadians May Not Know About: Rexulti Class Action Settlement

Deadline Many Canadians May Not Know About: Rexulti Class Action Settlement

If you or someone you care about has taken Rexulti, this information could be important. The deadline is approaching — and many people who may qualify might not even know about it.

A national class-action settlement has been reached involving Rexulti® (brexpiprazole), a medication used in the treatment of schizophrenia and as an add-on treatment for depression.

The settlement involves allegations that some people taking Rexulti experienced serious impulse-control problems, including behaviours such as compulsive gambling, spending, eating, or sexual behaviours. The companies involved have not admitted wrongdoing, but a $4.75 million settlement fund has been approved to compensate eligible Canadians.

The deadline is important: Claims must be submitted by August 27, 2026.

This is especially important because the people who may be affected are not always the ones who will see a headline, search online, or realize they might qualify.

Many people living with schizophrenia or depression already face enormous challenges. Medication decisions are often made during difficult periods of life, and side effects can sometimes be overlooked, misunderstood, or blamed on the person instead of being recognized as a possible medication-related issue.

That is why we need to help spread the word.

Please check on friends, family members, and community members

Do you know someone who has taken Rexulti?

Maybe:

• A family member who was prescribed it years ago.
• A friend who struggled with unusual spending or gambling after starting a medication.
• Someone living with schizophrenia who may not see this information online.
• A caregiver who manages appointments and paperwork for a loved one.

A simple conversation could make a difference.

You can ask:

“Did you ever take Rexulti? Did you know there may be a class-action settlement with a deadline coming up?”

Sharing information is not about telling someone what to do — it is about making sure people have the opportunity to find out if they qualify.

Important dates to remember

📌 February 16, 2017 – August 23, 2025: The general eligibility period for people who took Rexulti in Canada.
📌 August 27, 2026: Final deadline to submit a claim.

If you believe you or someone you know may qualify, look for the official settlement information and avoid unofficial websites asking for unnecessary personal information or payment.

Ten questions to reflect on

1. How many people might miss important legal deadlines because they never hear about them?
2. Do we do enough to reach people who are isolated, vulnerable, or dealing with health challenges?
3. How can families and caregivers help loved ones stay informed without taking away their independence?
4. Are medication side effects always recognized and reported when they happen?
5. How many people assume unusual changes in behaviour are “just who they are” instead of asking whether medication could be involved?
6. How can communities better share important information with people who do not use social media?
7. Do healthcare systems provide enough support after someone starts a powerful medication?
8. How can we make legal information easier to understand for everyone?
9. What responsibility do we have to check on friends who may not know about resources available to them?
10. Could one conversation today help someone meet a deadline tomorrow?

Information is power. A message shared with the right person at the right time can sometimes change a life.

Please share this with anyone who may have taken Rexulti or who supports someone who has.

#RexultiSettlement #Rexulti #MedicationAwareness #MentalHealthAwareness #SchizophreniaSupport #DepressionSupport #PatientRights #ClassActionSettlement #HealthcareAwareness #CommunityCare #ShareInformation #SupportEachOther

Keywords: Rexulti, brexpiprazole, Rexulti class action, Canadian settlement, medication awareness, schizophrenia, depression treatment, patient rights, pharmaceutical lawsuits, impulse control disorders, healthcare information, mental health support, caregiver awareness, Canadian class actions